Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
A phase 1/2 trial of Vimseltinib in tenosynovial giant cell tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.
Overview
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor is a phase 1/2 interventional study registered as NCT03069469 by Deciphera Pharmaceuticals, LLC, with 120 participants planned, started 2017-02-16 and due to reach its primary completion in 2028-08. Interventions recorded: Vimseltinib. Conditions listed: Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor. No results are recorded here; the registry entry is the source.
Setting
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Phase
Phase 1/2
Sponsor
Deciphera Pharmaceuticals, LLC
Registry
Enrolled
120